-
Efferocytosis in atherosclerosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-05-15 Shaunak S. Adkar, Nicholas J. Leeper
-
Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum Eur. Heart J. (IF 39.3) Pub Date : 2024-05-14 Avi Sabbag, Eivind W Aabel, Anna Isotta Castrini, Konstantinos C Siontis, Mikael Laredo, Jacky Nizard, Guillaume Duthoit, Samuel Asirvatham, Ojasay Sehrawat, Feddo P Kirkels, Philippe J van Rosendael, Roy Beinart, Moshe Rav Acha, Petr Peichl, Han S Lim, Christian Sohns, Raphael Martins, Jonaz Font, Nguyen N K Truong, Mette Estensen, Kristina H Haugaa
Background and Aims Arrhythmic mitral valve prolapse (AMVP) is linked to life-threatening ventricular arrhythmias (VAs), and young women are considered at high risk. Cases of AMVP in women with malignant VA during pregnancy have emerged, but the arrhythmic risk during pregnancy is unknown. The authors aimed to describe features of women with high-risk AMVP who developed malignant VA during the perinatal
-
Periprocedural myocardial infarction after percutaneous coronary intervention and long-term mortality: a meta-analysis Eur. Heart J. (IF 39.3) Pub Date : 2024-05-14 Luca Paolucci, Fabio Mangiacapra, Sara Sergio, Annunziata Nusca, Carlo Briguori, Emanuele Barbato, Gian Paolo Ussia, Francesco Grigioni
Background and Aims Conflicting data are available regarding the association between periprocedural myocardial infarction (PMI) and mortality following percutaneous coronary intervention. The purpose of this study was to evaluate the incidence and prognostic implication of PMI according to the Universal Definition of Myocardial Infarction (UDMI), the Academic Research Consortium (ARC)-2 definition
-
Activated factor X stimulates atrial endothelial cells and tissues to promote remodeling responses through AT1R/NADPH oxidases/SGLT1/2 Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-14 Walaa Fakih, Ali Mroueh, Dal-Seong Gong, Shinnosuke Kikuchi, Michael Paul Pieper, Michel Kindo, Jean-Philippe Mazzucottelli, Arnaud Mommerot, Mohamad Kanso, Patrick Ohlmann, Olivier Morel, Valérie Schini-Kerth, Laurence Jesel
Aims Atrial fibrillation (AF), the most common cardiac arrhythmia favoring ischemic stroke and heart failure involves left atrial remodeling, fibrosis and a complex interplay between cardiovascular risk factors. This study examined whether activated factor X (FXa) induces pro-remodeling and pro-fibrotic responses in atrial endothelial cells (AECs) and human atrial tissues and determined the underlying
-
Harnessing the potential of monocytes/macrophages to regenerate tissue engineered vascular grafts Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-14 Arundhati Das, Randall J Smith, Stelios T Andreadis
Cell-free tissue-engineered vascular grafts provide a promising alternative to treat cardiovascular disease but timely endothelialization is essential for ensuring patency and proper functioning post-implantation. Recent studies from our lab showed that blood cells like monocytes (MCs) and macrophages (Mφ) may contribute directly to cellularization and regeneration of bioengineered arteries in small
-
Inhibition of de novo ceramide synthesis by Sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-13 Srividya Velagapudi, Gergely Karsai, Maria Karsai, Shafeeq A Mohammed, Fabrizio Montecucco, Luca Liberale, Hwan Lee, Federico Carbone, Giovanni Francesco Adami, Kangmin Yang, Margot Crucet, Sokrates Stein, Franceso Paneni, Tetiana Lapikova-Bryhinska, Hyun-Duk Jang, Simon Kraler, Daria Vdovenko, Richard Arnold Züllig, Giovanni G Camici, Hyo-Soo Kim, Reijo Laaksonen, Philipp A Gerber, Thorsten Hornemann
Background Obesity and type 2 diabetes (T2D) are major risk factors for cardiovascular diseases (CVD). Dysregulated pro-apoptotic ceramide synthesis reduces β-cell insulin secretion, thereby promoting hyperglycemic states which may manifest as T2D. Pro-apoptotic ceramides modulate insulin sensitivity and glucose tolerance while being linked to poor cardiovascular outcomes. Sirtuin-1 (SIRT1) is a NAD
-
Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials Eur. Heart J. (IF 39.3) Pub Date : 2024-05-11 Sanjiv J Shah, Kavita Sharma, Barry A Borlaug, Javed Butler, Melanie Davies, Dalane W Kitzman, Mark C Petrie, Subodh Verma, Shachi Patel, Khaja M Chinnakondepalli, Mette N Einfeldt, Thomas J Jensen, Søren Rasmussen, Rabea Asleh, Tuvia Ben-Gal, Mikhail N Kosiborod
Background and Aims In the STEP-HFpEF trial program, treatment with semaglutide resulted in multiple beneficial effects in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to baseline diuretic use, and semaglutide treatment could modify diuretic dose. Methods In this pre-specified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF-DM
-
Identification of three mechanistic pathways for iron-deficient heart failure Eur. Heart J. (IF 39.3) Pub Date : 2024-05-11 Milton Packer, Stefan D Anker, Javed Butler, John G F Cleland, Paul R Kalra, Robert J Mentz, Piotr Ponikowski
Current understanding of iron-deficient heart failure is based on blood tests that are thought to reflect systemic iron stores, but the available evidence suggests greater complexity. The entry and egress of circulating iron is controlled by erythroblasts, which (in severe iron deficiency) will sacrifice erythropoiesis to supply iron to other organs, e.g. the heart. Marked hypoferraemia (typically
-
Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-10 M Trum, J Riechel, E Schollmeier, S Lebek, P Hegner, K Reuthner, S Heers, K Keller, M Wester, S Klatt, N Hamdani, Z Provaznik, C Schmid, L S Maier, M Arzt, S Wagner
Aims Heart failure with preserved ejection fraction (HFpEF) causes substantial morbidity and mortality. Importantly, atrial remodeling and atrial fibrillation is frequently observed in HFpEF. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently been shown to improve clinical outcomes in HFpEF, and post-hoc analyses suggest atrial antiarrhythmic effects. We tested if isolated human atrial
-
Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial Eur. Heart J. (IF 39.3) Pub Date : 2024-05-09 P R D Clephas, V W Zwartkruis, J Malgie, M W F van Gent, H P Brunner-La Rocca, M K Szymanski, V P van Halm, M L Handoko, W Kok, F W Asselbergs, R van Kimmenade, O Manintveld, N M D A van Mieghem, S L M A Beeres, M C Post, C J W Borleffs, R Tukkie, A Mosterd, G C M Linssen, R F Spee, M E Emans, T D J Smilde, J van Ramshorst, C Kirchhof, F Feenema–Aardema, C A da Fonseca, M van den Heuve, R Hazeleger
Background and Aims In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated the efficacy of pulmonary artery (PA)-guided HF therapy over standard of care in improving quality of life and reducing HF hospitalizations and mean PA pressure. This study aimed to evaluate the consistency of these benefits in relation to clinically relevant subgroups. Methods The effect of PA-guided
-
Inhibition of TBL1 cleavage alleviates doxorubicin-induced cardiomyocytes death by regulating the Wnt/β-catenin signal pathway Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-09 Sun-Ho Lee, Jangho Lee, Jaewon Oh, Jin-Taek Hwang, Hae-Jeung Lee, Hwa Kyung Byun, Hyeong-Jin Kim, David Suh, Ho-Geun Yoon, Sahng Wook Park, Seok-Min Kang, Chulan Kwon, Seung-Hyun Lee, Hyo-Kyoung Choi
Aims Doxorubicin (DOX) is a widely used anthracycline anticancer agent; however, its irreversible effects on the heart can result in DOX-induced cardiotoxicity (DICT) after cancer treatment. Unfortunately, the pathophysiology of DICT has not yet been fully elucidated, and there are no effective strategies for its prevention or treatment. In this investigation, the novel role of transducin beta-like
-
Role of endothelial Raptor in abnormal arteriogenesis after lower limb ischemia in type-2 diabetes Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-09 Ting Liu, Jiachen Zhang, Fangyuan Chang, Mengyu Sun, Jinlong He, Ding Ai
Aims Proper arteriogenesis after tissue ischemia is necessary to rebuild stable blood circulation; nevertheless, this process is impaired in type-2 diabetes mellitus (T2DM). Raptor, is a scaffold protein and a component of mammalian target of rapamycin complex 1 (mTORC1). However, the role of the endothelial Raptor in arteriogenesis under the conditions of T2DM remains unknown. This study investigated
-
Adenosine kinase inhibition protects mice from abdominal aortic aneurysm via epigenetic modulation of VSMC inflammation Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-09 Jiean Xu, Zhiping Liu, Qiuhua Yang, Qian Ma, Yaqi Zhou, Yongfeng Cai, Dingwei Zhao, Guizhen Zhao, Tammy Lu, Kunfu Ouyang, Mei Hong, Ha Won Kim, Huidong Shi, Jifeng Zhang, David Fulton, Clint Miller, Rajeev Malhotra, Neal L Weintraub, Yuqing Huo
Aim Abdominal aortic aneurysm (AAA) is a common, serious vascular disease with no effective pharmacological treatment. The nucleoside adenosine plays an important role in modulating vascular homeostasis, which prompted us to determine whether adenosine kinase (ADK), an adenosine metabolizing enzyme, modulates AAA formation via control of intracellular adenosine level, and to investigate the underlying
-
Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and High Bleeding Risk JAMA Cardiol. (IF 24.0) Pub Date : 2024-05-08 Andrea Erriquez, Gianluca Campo, Vincenzo Guiducci, Javier Escaned, Raul Moreno, Gianni Casella, Mila Menozzi, Enrico Cerrato, Giorgio Sacchetta, Alberto Menozzi, Ignacio Amat Santos, Enrique Gutiérrez Ibañes, Roberto Scarsini, Giuseppe Vadalà, Giuseppe Andò, José Luis Díez-Gil, Sergio Musto d’Amore, Alessandro Capecchi, Iginio Colaiori, Francesco Gallo, Rita Pavasini, Andrea Marrone, Graziella Pompei
ImportancePatients with high bleeding risk (HBR) have a poor prognosis, and it is not known if they may benefit from complete revascularization after myocardial infarction (MI).ObjectiveTo investigate the benefit of physiology-guided complete revascularization vs a culprit-only strategy in patients with HBR, MI, and multivessel disease.Design, Setting, and ParticipantsThis was a prespecified analysis
-
Underrepresentation of Women in Revascularization Trials JAMA Cardiol. (IF 24.0) Pub Date : 2024-05-08 Celina M. Yong, William F. Fearon
This Viewpoint discusses the unequal representation of women in coronary revascularization trials in the US, its negative effects on the cardiovascular health of both sexes, and potential mechanisms to ensure appropriate representation of women moving forward.
-
Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention? Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-05-07 Simone Fezzi, Daixin Ding, Felix Mahfoud, Jiayue Huang, Alexandra J. Lansky, Shengxian Tu, William Wijns
-
FLT4 causes developmental disorders of the cardiovascular and lymphovascular systems via pleiotropic molecular mechanisms Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-07 Richard M Monaghan, Richard W Naylor, Daisy Flatman, Paul R Kasher, Simon G Williams, Bernard D Keavney
Aims Rare, deleterious genetic variants in FLT4 are associated with Tetralogy of Fallot (TOF), the most common cyanotic congenital heart disease (CHD). Distinct genetic variants in FLT4 are also an established cause of Milroy disease, the most prevalent form of primary hereditary lymphoedema. Phenotypic features of these two conditions are non-overlapping, implying pleiotropic cellular mechanisms during
-
Modeling the Impact of Biomarker-Guided Versus ASCVD Risk–Guided Drug Treatment in US Adults With Stage 1 Hypertension: The National Health and Nutrition Examination Survey, 1999 to 2004 Hypertension (IF 8.3) Pub Date : 2024-05-01 Kathryn Foti, Dan Wang, Olive Tang, Natalie R. Daya, Yvonne Commodore-Mensah, Stephen P. Juraschek, Robert Christenson, Elizabeth Selvin, John W. McEvoy
BACKGROUND:Guidelines recommend antihypertensive medication for adults with both stage 1 hypertension (systolic blood pressure, 130–139 mm Hg or diastolic blood pressure, 80–89 mm Hg) and 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥10%. Cardiac biomarkers could facilitate a more targeted approach to the treatment of stage 1 hypertension.METHODS:We studied 1999 to 2004 National Health
-
Hypertension Impacts the Oscillatory Dynamics Serving the Encoding Phase of Verbal Working Memory Hypertension (IF 8.3) Pub Date : 2024-05-01 Yasra Arif, Abraham D. Killanin, Jingqi Zhu, Madelyn P. Willett, Hannah J. Okelberry, Hallie J. Johnson, Tony W. Wilson
BACKGROUND:Chronic hypertension is known to be a major contributor to cognitive decline, with executive function and working memory being among the domains most commonly affected. Despite the growing literature on such dysfunction in patients with hypertension, the underlying neural processes are poorly understood.METHODS:In this cross-sectional study, we examine these neural processes by having participants
-
Counteracting Angiotensinogen Small-Interfering RNA-Mediated Antihypertensive Effects With REVERSIR Hypertension (IF 8.3) Pub Date : 2024-05-01 Dien Ye, Edwyn O. Cruz-López, Richard van Veghel, Ingrid M. Garrelds, Anne Kasper, Kelly Wassarman, Ho-Chou Tu, Ivan Zlatev, A.H. Jan Danser
BACKGROUND:Ssmall-interfering RNA (siRNA) targeting hepatic AGT (angiotensinogen) mRNA depletes AGT, lowering blood pressure for up to 6 months. However, certain situations may require a rapid angiotensin increase. The reverse siRNA silencing, RVR technology is a potential approach to counteract siRNA effects.METHODS:Spontaneously hypertensive rats received 10 mg/kg AGT siRNA, and 3 weeks later were
-
Immunomodulatory Activity of Cytokines in Hypertension: A Vascular Perspective Hypertension (IF 8.3) Pub Date : 2024-04-30 Rinaldo R. dos Passos Jr, Cintia V. Santos, Fernanda Priviero, Ana M. Briones, Rita C. Tostes, R. Clinton Webb, Gisele F. Bomfim
Cytokines play a crucial role in the structure and function of blood vessels in hypertension. Hypertension damages blood vessels by mechanisms linked to shear forces, activation of the renin-angiotensin-aldosterone and sympathetic nervous systems, oxidative stress, and a proinflammatory milieu that lead to the generation of neoantigens and damage-associated molecular patterns, ultimately triggering
-
Spatiotemporal ATF3 Expression Determines VSMC Fate in Abdominal Aortic Aneurysm Circ. Res. (IF 20.1) Pub Date : 2024-04-30 Ying Wen, Yingying Liu, Qiang Li, Jinlin Tan, Xing Fu, Yiwen Liang, Yonghua Tuo, Luhao Liu, Xueqiong Zhou, Dongkai LiuFu, Xuejiao Fan, Chaofei Chen, Zheng Chen, Zhouping Wang, Shunyang Fan, Renjing Liu, Lei Pan, Yuan Zhang, Wai Ho Tang
BACKGROUND:Abdominal aortic aneurysm (AAA) is a catastrophic disease with little effective therapy, likely due to the limited understanding of the mechanisms underlying AAA development and progression. Activating transcription factor (ATF) 3 has been increasingly recognized as a key regulator of cardiovascular diseases. However, the role of ATF3 (activating transcription factor 3) in AAA development
-
Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial Circulation (IF 37.8) Pub Date : 2024-05-01 Duk-Hyun Kang, Sung-Ji Park, Sung-Hee Shin, In-Chang Hwang, Yeonyee Elizabeth Yoon, Hyung-Kwan Kim, Mijin Kim, Min-Seok Kim, Sung-Cheol Yun, Jong-Min Song, Seok-Min Kang
BACKGROUND:The morbidity and mortality rates of patients with heart failure (HF) and functional mitral regurgitation (MR) remain substantial despite guideline-directed medical therapy for HF. We evaluated the efficacy of ertugliflozin for reduction of functional MR associated with HF with mild to moderately reduced ejection fraction.METHODS:The EFFORT trial (Ertugliflozin for Functional Mitral Regurgitation)
-
Atherosclerosis Is a Smooth Muscle Cell–Driven Tumor-Like Disease Circulation (IF 37.8) Pub Date : 2024-04-30 Huize Pan, Sebastian E. Ho, Chenyi Xue, Jian Cui, Quinian S. Johanson, Nadja Sachs, Leila S. Ross, Fang Li, Robert A. Solomon, E. Sander Connolly Jr, Virendra I. Patel, Lars Maegdefessel, Hanrui Zhang, Muredach P. Reilly
BACKGROUND:Atherosclerosis, a leading cause of cardiovascular disease, involves the pathological activation of various cell types, including immunocytes (eg, macrophages and T cells), smooth muscle cells (SMCs), and endothelial cells. Accumulating evidence suggests that transition of SMCs to other cell types, known as phenotypic switching, plays a central role in atherosclerosis development and complications
-
PDZ-Binding Kinase, a Novel Regulator of Vascular Remodeling in Pulmonary Arterial Hypertension Circulation (IF 37.8) Pub Date : 2024-04-29 Zsuzsanna Bordan, Robert Batori, Stephen Haigh, Xueyi Li, Mary Louise Meadows, Zach L. Brown, Madison A. West, Kunzhe Dong, Weihong Han, Yunchao Su, Qian Ma, Yuqing Huo, Jiliang Zhou, Mahmoud Abdelbary, Jennifer Sullivan, Neal. L. Weintraub, David W. Stepp, Feng Chen, Scott A. Barman, David J.R. Fulton
BACKGROUND:Pulmonary arterial hypertension (PAH) is high blood pressure in the lungs that originates from structural changes in small resistance arteries. A defining feature of PAH is the inappropriate remodeling of pulmonary arteries (PA) leading to right ventricle failure and death. Although treatment of PAH has improved, the long-term prognosis for patients remains poor, and more effective targets
-
miR-369-3p ameliorates diabetes-associated atherosclerosis by regulating macrophage succinate-GPR91 signaling Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-04 Shruti Rawal, Vinay Randhawa, Syed Husain Mustafa Rizvi, Madhur Sachan, Akm Khyrul Wara, Daniel Pérez-Cremades, Robert M Weisbrod, Naomi M Hamburg, Mark W Feinberg
Aims Diabetes leads to dysregulated macrophage immunometabolism, contributing to accelerated atherosclerosis progression. Identifying critical factors to restore metabolic alterations and promote resolution of inflammation remains an unmet goal. MicroRNAs (miRs) orchestrate multiple signaling events in macrophages, yet their therapeutic potential in diabetes-associated atherosclerosis remains unclear
-
No benefit of apoA-I infusion after myocardial infarction Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-05-03 Gregory B. Lim
In the AEGIS-II trial, infusion of apolipoprotein A-I to increase cholesterol efflux capacity did not improve outcomes in patients with acute myocardial infarction.
-
Women With a History of Preeclampsia Exhibit Accelerated Aging and Unfavorable Profiles of Senescence Markers Hypertension (IF 8.3) Pub Date : 2024-05-01 Sonja Suvakov, Lisa E. Vaughan, Santosh Parashuram, Yvonne S. Butler Tobah, Muthuvel Jayachandran, Andrea Kattah, Alanna M. Chamberlain, Suzette J. Bielinski, Natasa Milic, Vesna D. Garovic
BACKGROUND:Senescence, a mechanism of cellular aging, which is characterized by irreversible proliferation arrest and a proinflammatory secretory phenotype, has been documented in women with preeclampsia. As cellular senescence can persist and progress, we postulated that it is associated with accelerated aging phenotype and accumulation of comorbidities in women with a history of preeclampsia.METHODS:We
-
Adult Congenital Heart Disease Circulation (IF 37.8) Pub Date : 2024-04-29 Mikael Dellborg
Congenital heart disease (CHD) is a field of cardiology where perhaps the most dramatic evolution has occurred over the last 40 to 50 years. The stunning development of antenatal diagnostics, interventional catheterization, cardiothoracic surgery, echocardiography, and pre- and postoperative intensive care as well as important pharmacological advances have improved prognosis during childhood. While
-
Stress and cardiovascular disease: an update Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-05-02 Viola Vaccarino, J. Douglas Bremner
-
Lower extremity arterial disease vs. coronary artery disease: mortality differences after revascularization Eur. Heart J. (IF 39.3) Pub Date : 2024-05-02 Mitsuyoshi Takahara, Yoshimitsu Soga, Osamu Iida
Background and Aims Patients undergoing revascularization for lower extremity arterial disease (LEAD) may face a higher risk of mortality than those with coronary artery disease (CAD). This study aimed to characterize the difference in mortality risk between patients undergoing revascularization for LEAD and CAD and identify associated factors. Methods The 1-year database of 10 754 patients undergoing
-
Targeting macrophages with multifunctional nanoparticles to detect and prevent atherosclerotic cardiovascular disease Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-02 Victoria Nankivell, Achini K Vidanapathirana, Ayla Hoogendoorn, Joanne T M Tan, Johan Verjans, Peter J Psaltis, Mark R Hutchinson, Brant C Gibson, Yiqing Lu, Eva Goldys, Gang Zheng, Christina A Bursill
Despite the emergence of novel diagnostic, pharmacological, interventional and prevention strategies, atherosclerotic cardiovascular disease remains a significant cause of morbidity and mortality. Nanoparticle-based platforms encompass diverse imaging, delivery and pharmacological properties that provide novel opportunities for refining diagnostic and therapeutic interventions for atherosclerosis at
-
Low-intensity pulsed ultrasound protects from inflammatory dilated cardiomyopathy through inciting extracellular vesicles Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-02 Ping Sun, Yi Li, Yifei Li, Huan Ji, Ge Mang, Shuai Fu, Shuangquan Jiang, Stephen Choi, Xiaoqi Wang, Zhonghua Tong, Chao Wang, Fei Gao, Pingping Wan, Shuang Chen, You Li, Peng Zhao, Xiaoping Leng, Maomao Zhang, Jiawei Tian
Aims CD4+ T cells are activated during inflammatory dilated cardiomyopathy (iDCM) development to induce immunogenic responses that damage the myocardium. Low-intensity pulsed ultrasound (LIPUS), a novel physiotherapy for cardiovascular diseases, has recently been shown to modulate inflammatory responses. However, its efficacy in iDCM remains unknown. Here, we investigated whether LIPUS could improve
-
Wide Complex Tachycardia in a Middle-Aged Woman With Diarrhea JAMA Cardiol. (IF 24.0) Pub Date : 2024-05-01 Matthew G. Peters, Nachiket Apte, Dinesh K. Kalra
A woman in her mid-60s with a history of paroxysmal atrial fibrillation and hypertension presents with 3 days of nausea, vomiting, and diarrhea. What would you do next?
-
Deep Learning–Based Assessment of Built Environment From Satellite Images and Cardiometabolic Disease Prevalence JAMA Cardiol. (IF 24.0) Pub Date : 2024-05-01 Zhuo Chen, Jean-Eudes Dazard, Yassin Khalifa, Issam Motairek, Catherine Kreatsoulas, Sanjay Rajagopalan, Sadeer Al-Kindi
ImportanceBuilt environment plays an important role in development of cardiovascular disease. Large scale, pragmatic evaluation of built environment has been limited owing to scarce data and inconsistent data quality.ObjectiveTo investigate the association between image-based built environment and the prevalence of cardiometabolic disease in urban cities.Design, Setting, and ParticipantsThis cross-sectional
-
The ketogenic diet does not improve cardiac function and blunts glucose oxidation in ischemic heart failure Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-01 Kim L Ho, Qutuba Karwi, Faqi Wang, Cory Wagg, Liyan Zhang, Sai Panidarapu, Brandon Chen, Simran Pherwani, Amanda A Greenwell, Gavin Oudit, John R Ussher, Gary D Lopaschuk
Aims Cardiac energy metabolism is perturbed in ischemic heart failure and is characterized by a shift from mitochondrial oxidative metabolism to glycolysis. Notably, the failing heart relies more on ketones for energy than a healthy heart, an adaptive mechanism that improves the energy-starved status of the failing heart. However, whether this can be implemented therapeutically remains unknown. Therefore
-
Embolic strokes of undetermined source: a clinical consensus statement of the ESC Council on Stroke, the European Association of Cardiovascular Imaging and the European Heart Rhythm Association of the ESC Eur. Heart J. (IF 39.3) Pub Date : 2024-04-30 George Ntaios, Helmut Baumgartner, Wolfram Doehner, Erwan Donal, Thor Edvardsen, Jeff S Healey, Bernard Iung, Hooman Kamel, Scott E Kasner, Eleni Korompoki, Babak B Navi, Christian Pristipino, Luca Saba, Renate B Schnabel, Emma Svennberg, Gregory Y H Lip
One in six ischaemic stroke patients has an embolic stroke of undetermined source (ESUS), defined as a stroke with unclear aetiology despite recommended diagnostic evaluation. The overall cardiovascular risk of ESUS is high and it is important to optimize strategies to prevent recurrent stroke and other cardiovascular events. The aim of clinicians when confronted with a patient not only with ESUS but
-
JACC Focus Seminar on Mechanical Complications of Acute Myocardial Infarction J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2024-04-29 Pedro R. Moreno MD, Valentin Fuster MD PhD
-
The Rise of 2 Interacting Subspecialties in Cardiology: Cardiometabolic Diseases and the Microcirculation J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2024-04-29 Viviany R. Taqueti MD MPH, Valentin Fuster MD PhD
-
Clonal Hematopoiesis Among Patients With Asymptomatic Carotid Stenosis Compounds Risk of Cardiovascular Death J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2024-04-29 Pradeep Natarajan MD MMSc, Tiffany R. Bellomo MD
-
Can Plaque Imaging Improve Risk Assessment Among Individuals With Elevated Lp(a)? J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2024-04-29 Ron Blankstein MD, Arthur Shiyovich MD
-
Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5 J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2024-04-29 Rodrigo Estévez-Loureiro MD PhD, Roberto Lorusso MD PhD, Maurizio Taramasso MD PhD, Gianluca Torregrossa MD, Annapoorna Kini MD, Pedro R. Moreno MD
-
Combined Effects of Clonal Hematopoiesis and Carotid Stenosis on Cardiovascular Mortality J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2024-04-29 Roland Jäger PhD, Matthias Hoke MD, Florian J. Mayer MD, Stefanie Boden BSc, Cornelia Englisch MD, Cihan Ay MD, Robert Kralovics PhD, Christoph J. Binder MD PhD
-
Right Ventricular Myocardial Infarction—A Tale of Two Ventricles: JACC Focus Seminar 1/5 J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2024-04-29 James A. Goldstein MD, Stamatios Lerakis MD, Pedro R. Moreno MD
-
Association of Lipoprotein(a) Levels With Myocardial Infarction in Patients With Low-Attenuation Plaque J. Am. Coll. Cardiol. (IF 24.0) Pub Date : 2024-04-29 Meng-Meng Yu MD, Ming-Liang Wang MD, Jin-Jin Wang MD, Bo-Li Lin MD, Xin Zhao MD, Xin-Wei Tao MD, Yin-Yin Chen MD, Peng-Yang Li MD, Jing-Kun Zhang MD, Jun-Bo Ge MD PhD, Hang Jin MD PhD, Meng-Su Zeng MD PhD
-
Long-term outcomes after hospitalization for atrial fibrillation or flutter Eur. Heart J. (IF 39.3) Pub Date : 2024-04-28 Linh Thi Hai Ngo, Yang Peng, Russell Denman, Ian Yang, Isuru Ranasinghe
Background and Aims Atrial fibrillation (AF) and flutter are common causes of hospitalizations but contemporary long-term outcomes following these episodes are uncertain. This study assessed outcomes up to 10 years after an acute AF or flutter hospitalization. Methods Patients hospitalized acutely with a primary diagnosis of AF or flutter from 2008–17 from all public and most private hospitals in Australia
-
Artificial Intelligence–Derived Risk Prediction: A Novel Risk Calculator Using Office and Ambulatory Blood Pressure Hypertension (IF 8.3) Pub Date : 2024-04-25 Pedro Guimarães, Andreas Keller, Michael Böhm, Lucas Lauder, Tobias Fehlmann, Luis M. Ruilope, Ernest Vinyoles, Manuel Gorostidi, Julián Segura, Gema Ruiz-Hurtado, Natalie Staplin, Bryan Williams, Alejandro de la Sierra, Felix Mahfoud
BACKGROUND:Quantification of total cardiovascular risk is essential for individualizing hypertension treatment. This study aimed to develop and validate a novel, machine-learning–derived model to predict cardiovascular mortality risk using office blood pressure (OBP) and ambulatory blood pressure (ABP).METHODS:The performance of the novel risk score was compared with existing risk scores, and the possibility
-
Sex-Related Disparities in Cardiovascular Outcomes Among Older Adults With Late-Onset Hypertension Hypertension (IF 8.3) Pub Date : 2024-04-25 Ann Bugeja, Celine Girard, Manish M. Sood, Claire E. Kendall, Ally Sweet, Ria Singla, Pouya Motazedian, Amanda J. Vinson, Marcel Ruzicka, Gregory L. Hundemer, Greg Knoll, Daniel I. McIsaac
BACKGROUND:It is unclear whether sex-based differences in cardiovascular outcomes exist in late-onset hypertension.METHODS:This is a population-based cohort study in Ontario, Canada of 266 273 adults, aged ≥66 years with newly diagnosed hypertension. We determined the incidence of the primary composite cardiovascular outcome (myocardial infarction, stroke, and congestive heart failure), all-cause mortality
-
Risk of Major Adverse Cardiovascular Events After Emergency Department Visits for Hypertensive Urgency Hypertension (IF 8.3) Pub Date : 2024-04-25 Ava L. Liberman, Junaid Razzak, Richard I. Lappin, Babak B. Navi, Samuel S. Bruce, Vanessa Liao, Jed H. Kaiser, Catherine Ng, Alan Z. Segal, Hooman Kamel
BACKGROUND:Chronic hypertension is an established long-term risk factor for major adverse cardiovascular events (MACEs). However, little is known about short-term MACE risk after hypertensive urgency, defined as an episode of acute severe hypertension without evidence of target-organ damage. We sought to evaluate the short-term risk of MACE after an emergency department (ED) visit for hypertensive
-
NETosis Drives Blood Pressure Elevation and Vascular Dysfunction in Hypertension Circ. Res. (IF 20.1) Pub Date : 2024-04-26 Jaya Krishnan, Elizabeth M. Hennen, Mingfang Ao, Annet Kirabo, Taseer Ahmad, Néstor de la Visitación, David M. Patrick
BACKGROUND:Neutrophil extracellular traps (NETs) are composed of nDNA, enzymes, and citrullinated histones that are expelled by neutrophils in the process of NETosis. NETs accumulate in the aorta and kidneys in hypertension. PAD4 (protein-arginine deiminase-4) is a calcium-dependent enzyme that is essential for NETosis. TRPV4 (transient receptor potential cation channel subfamily V member 4) is a mechanosensitive
-
Introduction to the Compendium On Environmental Impacts on Cardiovascular Health and Biology Circ. Res. (IF 20.1) Pub Date : 2024-04-25 Naomi M. Hamburg, Kathryn J. Moore
Our actions shape the world we live in. In turn, our natural, built, and social conditions shape our health. In recent years, the impact of environmental hazards on human health has emerged as an area of growing concern and intensive study. Among the various health issues linked to environmental factors, cardiovascular diseases are particularly notable due to their prevalence and their status as the
-
Impact of Wildfires on Cardiovascular Health Circ. Res. (IF 20.1) Pub Date : 2024-04-25 Victoria A. Williams, Luke R. Perreault, Charbel T. Yazbeck, Nicholas A. Micovic, Jessica M. Oakes, Chiara Bellini
Wildfire smoke (WFS) is a mixture of respirable particulate matter, environmental gases, and other hazardous pollutants that originate from the unplanned burning of arid vegetation during wildfires. The increasing size and frequency of recent wildfires has escalated public and occupational health concerns regarding WFS inhalation, by either individuals living nearby and downstream an active fire or
-
Understanding the Cardiovascular and Metabolic Health Effects of Air Pollution in the Context of Cumulative Exposomic Impacts Circ. Res. (IF 20.1) Pub Date : 2024-04-25 Haitham Khraishah, Zhuo Chen, Sanjay Rajagopalan
Poor air quality accounts for more than 9 million deaths a year globally according to recent estimates. A large portion of these deaths are attributable to cardiovascular causes, with evidence indicating that air pollution may also play an important role in the genesis of key cardiometabolic risk factors. Air pollution is not experienced in isolation but is part of a complex system, influenced by a
-
Heat and Cardiovascular Mortality: An Epidemiological Perspective Circ. Res. (IF 20.1) Pub Date : 2024-04-25 Nidhi Singh, Ashtyn Tracy Areal, Susanne Breitner, Siqi Zhang, Stefan Agewall, Tamara Schikowski, Alexandra Schneider
As global temperatures rise, extreme heat events are projected to become more frequent and intense. Extreme heat causes a wide range of health effects, including an overall increase in morbidity and mortality. It is important to note that while there is sufficient epidemiological evidence for heat-related increases in all-cause mortality, evidence on the association between heat and cause-specific
-
Transportation Noise Pollution and Cardiovascular Health Circ. Res. (IF 20.1) Pub Date : 2024-04-25 Thomas Münzel, Michael Molitor, Marin Kuntic, Omar Hahad, Martin Röösli, Nicole Engelmann, Mathias Basner, Andreas Daiber, Mette Sørensen
Epidemiological studies have found that transportation noise increases the risk for cardiovascular morbidity and mortality, with solid evidence for ischemic heart disease, heart failure, and stroke. According to the World Health Organization, at least 1.6 million healthy life years are lost annually from traffic-related noise in Western Europe. Traffic noise at night causes fragmentation and shortening
-
Perfluoroalkyl/Polyfluoroalkyl Substances: Links to Cardiovascular Disease Risk Circ. Res. (IF 20.1) Pub Date : 2024-04-25 Jennifer J. Schlezinger, Noyan Gokce
Conservative estimates by the World Health Organization suggest that at least a quarter of global cardiovascular diseases are attributable to environmental exposures. Associations between air pollution and cardiovascular risk have garnered the most headlines and are strong, but less attention has been paid to other omnipresent toxicants in our ecosystem. Perfluoroalkyl and polyfluoroalkyl substances
-
Heavy Metal Exposure and Cardiovascular Disease Circ. Res. (IF 20.1) Pub Date : 2024-04-25 Ziwei Pan, Tingyu Gong, Ping Liang
Heavy metals are harmful environmental pollutants that have attracted widespread attention due to their health hazards to human cardiovascular disease. Heavy metals, including lead, cadmium, mercury, arsenic, and chromium, are found in various sources such as air, water, soil, food, and industrial products. Recent research strongly suggests a connection between cardiovascular disease and exposure to
-
Personal Strategies to Reduce the Cardiovascular Impacts of Environmental Exposures Circ. Res. (IF 20.1) Pub Date : 2024-04-25 Luke J. Bonanni, Jonathan D. Newman
Ubiquitous environmental exposures increase cardiovascular disease risk via diverse mechanisms. This review examines personal strategies to minimize this risk. With regard to fine particulate air pollution exposure, evidence exists to recommend the use of portable air cleaners and avoidance of outdoor activity during periods of poor air quality. Other evidence may support physical activity, dietary
-
Transportation-Related Carbon Footprint of Coronary Heart Disease Ambulatory Care in the United States Circ. Res. (IF 20.1) Pub Date : 2024-04-25 Pedro R.V.O. Salerno, Zhuo Chen, Brendan Bourges-Sevenier, Alice Qian, Salil Deo, Khurram Nasir, Sanjay Rajagopalan, Sadeer Al-Kindi
As the leading cause of death in the United States, managing coronary heart disease (CHD) is not only a critical objective of the health care system but also a source of resource utilization. With the United States emitting a quarter of the world’s health care-related carbon footprint, the impact of health care access on travel-related carbon emissions must also be examined.1,2 Thus, we investigated
-
Association of Ecoregion Distribution of Greenness With Cardiovascular Mortality: A Longitudinal Ecological Study in the United States Circ. Res. (IF 20.1) Pub Date : 2024-04-25 Daniel W. Riggs, Natalie C. DuPre, Peter James, Shesh N. Rai, Ray Yeager, Clara G. Sears, Francine Laden, Aruni Bhatnagar
Evidence indicates that living in areas of high greenness is associated with lower rates of cardiovascular and all-cause mortality.1 However, specific health-promoting characteristics of greenness have not been identified, and how greenness interacts with the surrounding ecology to promote human health remains unclear. Identifying the vegetation type, characteristics, and extent of greenness that is